Citations |
- Narita M, et al., WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci. 7: 72?|81 (2010)(PMID:20428337)
- Saitoh A, et al., WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Med. Oncol. 28: 219?|230 (2011)(PMID:20107936)
- Chiba Y, et al., Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn. J. Clin. Oncol. 40: 395?|403 (2010)(PMID:20364021)
- Tsuboi A, et al., Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int. J. Hematol. 86: 414?|417 (2007)(PMID:18192109)
- Lu X et al. Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer. Am J Cancer Res. 8, 1564-1575 (2018)(PMID:30210924)
|